ALSO NOTED: Pharmacopeia gains funds in research deal; Serono sees better response for Rebiff formulation; and much more...

> Pharmacopeia Drug Discovery is gaining new research funds from an extension of its development pact with Schering-Plough. Schering-Plough is funding 10 full-time researchers along with milestones for new drug candidates. The collaboration is being extended to April 2007. Report

> Serono announced that new data shows that a new formulation of its bestselling Rebiff for MS shows that it has improved tolerability and antibody formation. Report

> Nitec Pharma announced positive results in a Phase III clinical trial with Lodotra, a modified-release tablet that has been developed to optimize the efficacy of orally administered low-dose prednisone in rheumatoid arthritis. Release

> Inyx Pharma has inked a deal to buy Pharmapac UK, a contract pharmaceutical production and packaging provider, for $17 million. Release

> Shares of Germany's MediGene were buoyed by the news that it had received a patent on its cancer drug candidate EndoTag-1. Report

> Discovery Laboratories says it has addressed the FDA's concerns on Surfaxin and is seeking a meeting with regulators to push for approval of the lung therapy. Report

> EpiCept's stock jumped after its collaborator Myriad Genetics reported positive Phase I data for a new brain cancer therapy, Azixa. Report

> Threshold Pharmaceuticals has won orphan drug status for its pancreatic cancer therapy glufosfamide. Report

> Researchers have concluded that the active ingredient in Accutane appears to cause depression-related symptoms in mice. Report

> GlaxoSmithKline has licensed a Chinese company to manufacture Relenza for stockpiles against a potential bird flu pandemic. Report

> XOMA announced it will manufacture and supply AV-299, AVEO's anti-HGF antibody, in support of early clinical trials. Release

And Finally…In an editorial, The New York Times supports the IOM's position urging additional funding for the FDA. Editorial

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.